TL;DR: Nephrogen is a Y Combinator Summer 2020 startup Curative genetic medicines for kidney diseases, currently active with a team of 5.
Curative genetic medicines for kidney diseases
Last verified:
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
Built by LemStudio
Yes. Nephrogen was funded by Y Combinator in the Summer 2020 batch. Curative genetic medicines for kidney diseases
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, mo…
Nephrogen was part of Y Combinator's Summer 2020 batch.
Nephrogen has a team of 5 people according to Y Combinator's directory.
Nephrogen is currently listed as Active with a team of 5 in Y Combinator's directory.
Loading interactive view…